We are live on ! Find out more
ADMA icon

ADMA Biologics
ADMA

Fund managers haven’t disclosed any holdings of ADMA yet.

ADMA Hedge Fund Activity: Q1 2026 in Review

356 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2026, worth a combined $1.91B — down 52% from $4.02B a quarter earlier.

Buyers outnumbered sellers: 70 funds opened new ADMA positions and 61 closed out — a net gain of 9 holders — while 135 added to existing stakes and 109 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $71.9M. The largest seller was Sachem Head Capital Management, exiting entirely with an estimated $207M sold.

  • 356 institutional investors held ADMA Biologics (ADMA) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $1.91B of ADMA Biologics stock for Q1 2026, down 52% quarter-over-quarter.
  • 70 funds opened new ADMA Biologics positions in Q1 2026 and 61 closed out, a net change of +9 holders.
  • The largest ADMA Biologics buyer in Q1 2026 was Capital Research Global Investors, an estimated $71.9M added.
  • The largest ADMA Biologics seller in Q1 2026 was Sachem Head Capital Management, an estimated $207M sold.

Based on aggregated 13F filings for Q1 2026.